Med

, volume 5 , issue 10 , pages 1237-1254.e9

Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer

Zhuoran Yao ^{1, 2}

Kai Kang ^{1, 2}

Lin Zhou ^{1, 2}

Weigang Xiu ²

Jianguo Sun ³

Cong-hua Xie ⁴

Min Yu ²

Yanying Li ²

Yan Zhang ^{2, 5}

Yue Zheng ²

Lin Guo ²

Xiangyu Pan ⁶

Yijun Wu ^{1, 2}

R Luo ^{1, 2}

Laduona Wang ²

Min Moon Tang ²

Shuangsi Liao ²

Jiang Zhu ²

Xiaojuan Zhou ^{1, 2}

Xuanwei Zhang ^{1, 2}

Yong Xu ^{1, 2}

Yongmei Liu ^{1, 2}

Feng Peng ^{2, 7}

Jin Wang ^{1, 2}

Lisha Xiang ²

Limei Yin ^{2, 8}

Lei Deng ⁹

Meijuan Huang ²

Youling Gong ^{1, 2}

Tongfeng Zhang ¹⁰

Hui Wang ¹⁰

Wu Lin ¹¹

Zhiyong Yuan ¹²

Nan Bi ⁷

Min Fan ¹³

Yaping Xu ¹⁴

Ruizhan Tong ²

Linglu Yi ²

Lu Gan ¹⁵

Jianxin Xue ^{1, 2}

Bingwen Zou ^{1, 2}

XIANMING MO ¹⁶

Chong Chen ⁶

Feifei Na ²

You Lu ^{1, 2}

Hide authors affiliations Show authors affiliations: 16 affiliations

Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China |

Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China |

Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China

Chongqing Medical University

Army Medical University

⁴

Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China |

⁵

Center of Lung Cancer, West China Hospital, Sichuan University, Chengdu, China |

⁶

State Key Laboratory of Biotherapy and cancer center, West China Hospital, Sichuan University, Chengdu, China |

⁷

Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China |

⁸

Department of Health Management & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China |

⁹

University of Washington School of Medicine/Fred Hutchinson Cancer Center, Seattle, WA, USA

University of Washington

Fred Hutchinson Cancer Center

¹⁰

Department of Radiation Oncology, Hunan Cancer Hospital, Changsha, China |

¹¹

Department of Thoracic Medicine, Hunan Cancer Hospital, Changsha, China |

¹²

Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China |

¹³

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, shanghai, China |

¹⁴

Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China |

¹⁵

Research Laboratory of Emergency Medicine, Department of Emergency Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China |

¹⁶

Laboratory of Stem Cell Biology, West China Hospital, Sichuan University, Chengdu, China |

Publication type: Journal Article

Publication date: 2024-10-01

Elsevier

Med

scimago Q1

wos Q1

SJR: 3.815

CiteScore: 17.2

Impact factor: 11.8

ISSN: 26666340, 26666359

DOI: 10.1016/j.medj.2024.06.002

Copy DOI

PubMed ID: 38964333

Abstract

Immune checkpoint inhibitors (ICIs) provide modest but unsatisfactory benefits for extensive-stage small cell lung cancer (ES-SCLC). Developing strategies for treating ES-SCLC is critical.

Found

Top-30

Journals

	1 2 3
Frontiers in Immunology	Frontiers in Immunology, 3, 12.5% Frontiers in Immunology 3 publications, 12.5%
BMC Cancer	BMC Cancer, 3, 12.5% BMC Cancer 3 publications, 12.5%
Journal of Translational Medicine	Journal of Translational Medicine, 2, 8.33% Journal of Translational Medicine 2 publications, 8.33%
International Journal of Radiation Oncology Biology Physics	International Journal of Radiation Oncology Biology Physics, 2, 8.33% International Journal of Radiation Oncology Biology Physics 2 publications, 8.33%
Frontiers in Oncology	Frontiers in Oncology, 2, 8.33% Frontiers in Oncology 2 publications, 8.33%
Current Opinion in Oncology	Current Opinion in Oncology, 1, 4.17% Current Opinion in Oncology 1 publication, 4.17%
Discover Oncology	Discover Oncology, 1, 4.17% Discover Oncology 1 publication, 4.17%
Journal of Hematology and Oncology	Journal of Hematology and Oncology, 1, 4.17% Journal of Hematology and Oncology 1 publication, 4.17%
Biochimica et Biophysica Acta - Reviews on Cancer	Biochimica et Biophysica Acta - Reviews on Cancer, 1, 4.17% Biochimica et Biophysica Acta - Reviews on Cancer 1 publication, 4.17%
Biologics: Targets and Therapy	Biologics: Targets and Therapy, 1, 4.17% Biologics: Targets and Therapy 1 publication, 4.17%
Cell Death and Disease	Cell Death and Disease, 1, 4.17% Cell Death and Disease 1 publication, 4.17%
Journal of Cancer Research and Therapeutics	Journal of Cancer Research and Therapeutics, 1, 4.17% Journal of Cancer Research and Therapeutics 1 publication, 4.17%
Translational Lung Cancer Research	Translational Lung Cancer Research, 1, 4.17% Translational Lung Cancer Research 1 publication, 4.17%
Experimental Hematology and Oncology	Experimental Hematology and Oncology, 1, 4.17% Experimental Hematology and Oncology 1 publication, 4.17%
Clinical and Translational Immunology	Clinical and Translational Immunology, 1, 4.17% Clinical and Translational Immunology 1 publication, 4.17%
Therapeutic Advances in Medical Oncology	Therapeutic Advances in Medical Oncology, 1, 4.17% Therapeutic Advances in Medical Oncology 1 publication, 4.17%
	1 2 3

Publishers

	2 4 6 8 10
Springer Nature	Springer Nature, 10, 41.67% Springer Nature 10 publications, 41.67%
Frontiers Media S.A.	Frontiers Media S.A., 5, 20.83% Frontiers Media S.A. 5 publications, 20.83%
Elsevier	Elsevier, 3, 12.5% Elsevier 3 publications, 12.5%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 2, 8.33% Ovid Technologies (Wolters Kluwer Health) 2 publications, 8.33%
Taylor & Francis	Taylor & Francis, 1, 4.17% Taylor & Francis 1 publication, 4.17%
AME Publishing Company	AME Publishing Company, 1, 4.17% AME Publishing Company 1 publication, 4.17%
Wiley	Wiley, 1, 4.17% Wiley 1 publication, 4.17%
SAGE	SAGE, 1, 4.17% SAGE 1 publication, 4.17%
	2 4 6 8 10

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Yao Z. et al. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer // Med. 2024. Vol. 5. No. 10. p. 1237-1254.e9.

GOST all authors (up to 50) Copy

Yao Z. et al. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer // Med. 2024. Vol. 5. No. 10. p. 1237-1254.e9.

RIS |

Cite this

RIS

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2024_Yao,

author = {Zhuoran Yao and Kai Kang and Lin Zhou and Weigang Xiu and Jianguo Sun and Cong-hua Xie and Min Yu and Yanying Li and Yan Zhang and Yue Zheng and Lin Guo and Lin Guo and Xiangyu Pan and Yijun Wu and R Luo and Laduona Wang and Min Moon Tang and Shuangsi Liao and Jiang Zhu and Xiaojuan Zhou and Xuanwei Zhang and Yong Xu and Yongmei Liu and Feng Peng and Jin Wang and Lisha Xiang and Limei Yin and Lei Deng and Meijuan Huang and Youling Gong and Tongfeng Zhang and Hui Wang and Wu Lin and Zhiyong Yuan and Nan Bi and Min Fan and Yaping Xu and Ruizhan Tong and Linglu Yi and Lu Gan and Jianxin Xue and Bingwen Zou and XIANMING MO and Chong Chen and Feifei Na and You Lu and others},

title = {Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer},

journal = {Med},

year = {2024},

volume = {5},

publisher = {Elsevier},

month = {oct},

url = {https://linkinghub.elsevier.com/retrieve/pii/S2666634024002484},

number = {10},

pages = {1237--1254.e9},

doi = {10.1016/j.medj.2024.06.002}

}

MLA

Cite this

MLA Copy

Yao, Zhuoran, et al. “Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer.” Med, vol. 5, no. 10, Oct. 2024, pp. 1237-1254.e9. https://linkinghub.elsevier.com/retrieve/pii/S2666634024002484.

Publisher

Elsevier

Journal

Med

scimago Q1

wos Q1

SJR

3.815

CiteScore

17.2

Impact factor

11.8

ISSN

26666340 (Print)

26666359

Profiles